Spotlight
Clinical
CME
Partners
Highlighting results from first FDA-reported study for treatment of presbyopia
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Listen to the findings from the first FDA-reported study of a presbyopia-treatment eye drop.
George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Watch the interview: Analyzing GEMINI clinical trial results of presbyopia eye drop
Related Videos
Related Content
Pinpointing neurologic dysfunction in fundus photographs using deep learning analysis
March 26th 2023
Pinpointing neurologic dysfunction in fundus photographs using deep learning analysis
March 26th 2023
